Viking Therapeutics Inc (VKTX)
52.59
+0.96
(+1.86%)
USD |
NASDAQ |
Nov 22, 16:00
52.65
+0.06
(+0.11%)
After-Hours: 20:00
Viking Therapeutics Cash from Financing (Quarterly): 2.522M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.522M |
| June 30, 2024 | 2.905M |
| March 31, 2024 | 606.04M |
| December 31, 2023 | 0.188M |
| September 30, 2023 | -0.074M |
| June 30, 2023 | 267.08M |
| March 31, 2023 | 4.184M |
| December 31, 2022 | 10.75M |
| September 30, 2022 | 0.01M |
| June 30, 2022 | -1.59M |
| March 31, 2022 | -5.006M |
| December 31, 2021 | 0.047M |
| September 30, 2021 | -0.256M |
| June 30, 2021 | 1.898M |
| March 31, 2021 | 5.191M |
| December 31, 2020 | 0.464M |
| September 30, 2020 | 0.037M |
| June 30, 2020 | 0.416M |
| March 31, 2020 | 0.033M |
| December 31, 2019 | 0.229M |
| September 30, 2019 | 0.073M |
| June 30, 2019 | 0.26M |
| March 31, 2019 | 0.325M |
| Date | Value |
|---|---|
| December 31, 2018 | 0.343M |
| September 30, 2018 | 167.48M |
| June 30, 2018 | 70.15M |
| March 31, 2018 | 62.30M |
| December 31, 2017 | 14.76M |
| September 30, 2017 | 1.111M |
| June 30, 2017 | 4.002M |
| March 31, 2017 | 2.524M |
| December 31, 2016 | 1.038M |
| September 30, 2016 | 0.1083M |
| June 30, 2016 | 9.259M |
| March 31, 2016 | -0.0573M |
| December 31, 2015 | -0.0282M |
| September 30, 2015 | -0.7047M |
| June 30, 2015 | 22.96M |
| March 31, 2015 | -0.0179M |
| December 31, 2014 | 0.4024M |
| September 30, 2014 | 0.5128M |
| June 30, 2014 | 1.252M |
| March 31, 2014 | -0.00 |
| June 30, 2013 | 0.2154M |
| March 31, 2013 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-5.006M
Minimum
Mar 2022
606.04M
Maximum
Mar 2024
44.75M
Average
0.3225M
Median
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | -3.651B |
| Eli Lilly and Co | 211.30M |
| Pfizer Inc | -4.636B |
| Structure Therapeutics Inc | -0.757M |
| Altimmune Inc | 0.266M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -21.96M |
| Cash from Investing (Quarterly) | 25.90M |
| Free Cash Flow | -74.25M |
| Free Cash Flow Per Share (Quarterly) | -0.198 |
| Free Cash Flow Yield | -1.33% |